Xiamen Treatgut Biotechnology

Xiamen Treatgut Biotechnology is a clinical-stage biotechnology company focused on the development of next-generation live biotherapeutic products (LBPs) targeting the human gut microbiome. The company utilizes a proprietary platform for the isolation, characterization, and anaerobic fermentation of novel bacterial strains to address unmet needs in metabolic, neurological, and immunological health. Their research emphasizes the gut-brain and gut-skin axes, with a pipeline featuring candidates for obesity, autism spectrum disorder, and atopic dermatitis. Treatgut maintains integrated research and GMP-compliant manufacturing capabilities in Xiamen to support the rapid development of both single-strain and microbial consortia therapies. The company aims to translate microbiome science into standardized medical treatments for chronic and complex diseases.